We are live on
!
Find out more
KL
Kam Lawrence Portfolio holdings
AUM
$97.4M
This Fund
S&P 500
This Quarter
Est. Return
+69.01%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.4M
AUM Growth
–
Cap. Flow
+$81M
Cap. Flow
% of AUM
83.22%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
7
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$35.6M |
| 2 |
Regenxbio
RGNX
|
+$18.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$11.4M |
| 4 |
Genworth Financial
GNW
|
+$8.82M |
| 5 |
Fennec Pharmaceuticals
FENC
|
+$4.48M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 87.92% |
| 2 | Financials | 11.93% |
| 3 | Materials | 0.15% |
Similar funds
WCM
SIG
CCIM
CCM
BCFA
AC
WEC
BI
Kam Lawrence's Q4 2019 Portfolio in Review
Q4 2019 is the first quarter with a 13F filing on record for Kam Lawrence, which disclosed 7 positions worth $97.4M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Adverum Biotechnologies: 404,321 shares worth $46.6M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, followed by Financials and Materials.
- Kam Lawrence's largest Q4 2019 buy was Adverum Biotechnologies: 404,321 shares worth $46.6M.
- Kam Lawrence's ten largest holdings make up 100% of its $97.4M portfolio in Q4 2019.
- Kam Lawrence disclosed 7 positions in Q4 2019, its first 13F filing on record.
Based on Kam Lawrence's 13F filing for Q4 2019, filed 13 Feb 2020.